Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
(Exenatide is FDA approved as monotherapy for the management of T2DM.) Explicitly stated in the guideline for patients requiring dual or triple therapy, the AACE/ACE preferentially recommends the addition of a GLP-1 receptor agonist or a DPP-4 inhibitor (sitagliptin, saxagliptin), citing their efficacy and safety profiles as preferred agents over TZDs or sulfonylureas (SUs)
The siRNA duplexes were delivered into cells by transfection using Lipofectamine 2000 (Invitrogen)
Application of clinical judgment is necessary
coli DNA polymerase via nick-translation
Adrenal or thyroid disease: DSIP can interact with HPA-axis signaling
US$ 26.92
US$ 24.90
US$ 23.75
US$ 23.54
US$ 23.67
US$ 26.44
US$ 21.69
US$ 23.69
